HeXun Biosciences

HeXun Biosciences is a Taiwan-based biotech company specializing in new drug development through cell therapy (using mesenchymal stem cells) and exosome-based therapies. It operates a mature CDMO/CMO business, positioning itself among Taiwan's leading cell manufacturing companies. The company's technology, including UC-MSC culture and exosome production, has been licensed to partners like JY BioMed. HeXun's clinical focus is on exosome and mesenchymal stem cell drugs in early (pre-clinical) stages for indications such as wound healing and cardiovascular diseases, alongside commercial services in testing, filling, and consultation. The company has a core focus on regenerative and aesthetic medicine and went public on the Taipei Exchange in 2023.